Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 19;11:675104. doi: 10.3389/fonc.2021.675104

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Ye, An, Wang, Zhang, Huang, Sun, Li, Ma, Wang and Gao

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Association between ALOX5AP expression and clinicopathologic characteristics. Comparison of ALOX5AP expression in different clinical conditions including: (A) lymphatic invasion, (B) tumor residual, (C) primary therapy outcome and (D) platinum response. (E) Receiver operating characteristic (ROC) curve was drawn to analyze the predictive value of ALOX5AP for platinum-containing chemotherapy responsiveness. (F) The gene effect of ALOX5AP on cisplatin responsiveness of ovarian adenocarcinoma cell lines. Kaplan Meier curves of SOC patients receipt of platinum-based chemotherapy with high or low ALOX5AP expression in (G) pooled SOC patient cohorts, (H) TCGA-OV cohort, and (I) stage 3-4 SOC patient cohorts. (NRD, no residual disease; RD, residual disease; CR, complete response; PR, partial response).